Immunoproteasome inhibitors

1. A compound of Formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

W is —O—P-Q-C(R 8a )═C(R 8b )(R 8c ), —N(R′)—P-Q-C(R 8a )═C(R 8b )(R 8c ), or a group of formula

A 1 is hydrogen, hydroxy, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, or —S(═O) 2 -alkyl, wherein said alkyl of said —S(═O) 2 -alkyl is optionally substituted;

R′ is H or optionally substituted alkyl;

each R 1 is H or optionally substituted alkyl;

P is -alkyl-, -alkyl-O-alkyl-, -alkyl-N(R)—, -alkyl-aryl-N(R)—, -alkyl-N(R)-aryl-N(R)—, -alkyl-O-aryl-N(R)—, -alkyl-aryl-alkyl-N(R)—, -alkyl-heteroaryl-N(R)—, -alkyl-cycloalkyl-N(R)—, -alkyl-O-cycloalkyl-N(R)—, -alkyl-N(R)-cycloalkyl-N(R)—, -alkyl-O-alkyl-N(R)—, -alkyl-N(R)-alkyl-N(R)—,

 or

 wherein each instance of alkyl, aryl, heteroaryl, and cycloalkyl is optionally substituted;

Z and Z 1 are independently a covalent bond, -alkyl-, -alkyl-O—, -alkyl-N(R)—, or -alkyl-O-alkyl-, wherein each instance of alkyl is optionally substituted;

ring A with the ring nitrogen atom shown is an optionally substituted saturated mono- or multicyclic 4 to 10 membered heterocyclyl;

ring J with the ring nitrogen atom and ring Y 1 atom shown is an optionally substituted saturated 4 to 10 membered heterocyclyl;

Y 1 is C or N;

Z 2 is a covalent bond or N(R);

each R is independently hydrogen or optionally substituted alkyl;

Q is —C(═O)— or —S(═O) 2 —;

each R 8a independently is hydrogen, halogen, or cyano;

each R 8b independently is hydrogen or optionally substituted alkyl; or

each R 8a and R 8b independently are taken together to form a bond; and

each R 8c independently is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, or optionally substituted heterocyclyl;

R b1 is optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, or optionally substituted heterocyclyl;

R b2 and R b3 are independently hydrogen or optionally substituted C 1-6 alkyl; or

R b2 and R b3 together with the boron atom to which they are shown attached form an optionally substituted cyclic boronic ester having 2 to 20 carbons, and optionally containing one or two additional cyclic heteroatoms chosen from N, O and S; and

m and n are independently 0 or 1;

provided that when W is —O—P-Q-C(R 8a )═C(R 8b )(R 8c ), or a group of formula

wherein m and n are each 0, then P is not -alkyl-N(R)—, -alkyl-(C 3 -C 6 ) cycloalkyl-N(R)—, alkyl-O-alkyl-N(R)—, or

 wherein each instance of alkyl, and cycloalkyl is optionally substituted, ring A with the ring nitrogen atom as shown is an optionally substituted saturated monocyclic five- to seven-membered heterocyclyl with only the one nitrogen shown as the ring heteroatom, and wherein Z is connected to ring A at a carbon atom adjacent to the ring nitrogen atom; and

provided that when W is —O—P-Q-C(R 8a )═C(R 8b )(R 8c ), or a group of formula

wherein m and n are each 0, and P is

wherein Y 1 in ring J is nitrogen, then Z 2 is a covalent bond.

2. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein:

said -alkyl-N(R)— of P is —(CH 2 ) 1-4 N(R)—;

said -alkyl-aryl-N(R)— of P is —(CH 2 ) 1-4 -phenyl-N(R)—;

said -alkyl-N(R)-aryl-N(R)— of P is —(CH 2 ) 1-4 —N(R)-phenyl-N(R)—;

said -alkyl-O-aryl-N(R)— of P is —(CH 2 ) 1-4 —O-phenyl-N(R)—;

said -alkyl-aryl-alkyl-N(R)— of P is —(CH 2 ) 1-4 -phenyl-(CH 2 ) 1-4 N(R)—;

said -alkyl-heteroaryl-N(R)— of P is —(CH 2 ) 1-4 -heteroaryl-N(R)—;

said -alkyl-O-alkyl-N(R)— of P is —(CH 2 ) 1-4 —O—(CH 2 ) 1-4 N(R)—;

said -alkyl- of Z in

of P is —(CH 2 ) 1-4 —;

said -alkyl-O— of Z in

of P is —(CH 2 ) 1-4 —O—;

said -alkyl-N(R)— of Z in

of P is —(CH 2 ) 1-4 —N(R)—, wherein R is H, unsubstituted alkyl, or alkyl substituted with an alkoxy;

said -alkyl-O-alkyl- of Z in

of P is —(CH 2 ) 1-4 —O—(CH 2 ) 1-4 —;

said

in said

of P is a mono- or multicyclic heterocyclyl;

said Z 1 in said

of P is —(CH 2 ) 1-4 —; and

said ring J in said

of P is heterocyclyl;

wherein each phenyl and each heterocyclyl is independently optionally substituted with 1-3 substituents independently chosen from halo, hydroxy, alkyl, alkoxy, cyano, haloalkyl, —NH 2 , —NH(alkyl), —N(alkyl) 2 , heterocyclyl, aryl, and heteroaryl.

3. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein:

said -alkyl-N(R)— of P is

said -alkyl-aryl-N(R)— of P is

said -alkyl-N(R)-aryl-N(R)— of P is

said -alkyl-O-aryl-N(R)— of P is

said -alkyl-aryl-alkyl-N(R)— of P is

said -alkyl-heteroaryl-N(R)— of P is

said -alkyl-O-alkyl-N(R)— of P is

said

of P is

and

said

of P is

4. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein the optional substituents of said alkyl of R 8c are 1-3 substituents independently chosen from halo, hydroxy, alkoxy, cyano, —NH 2 , —SH, —C(═O)-alkyl, —C(═O)—O—alkyl, —O-alkyl-O-alkyl, —NH(alkyl), —NH(optionally substituted cycloalkyl), —NH(alkyl-O-alkyl), —N(alkyl) 2 , —NH(optionally substituted heterocyclyl), —N(alkyl)(optionally substituted heterocyclyl), —N(optionally substituted cycloalkyl)(optionally substituted heterocyclyl), optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; and wherein the optional substituents of each of said cycloalkyl, heteroaryl, and heterocyclyl of R 8c are 1-3 substituents independently chosen from halo, hydroxy, alkyl, alkoxy, cyano, haloalkyl, —NH 2 , —SH, —C(═O)-alkyl, —C(═O)—O-alkyl, —O-alkyl-O-alkyl, —NH(alkyl), —NH(optionally substituted cycloalkyl), —NH(alkyl-O-alkyl), —N(alkyl) 2 , —NH(optionally substituted heterocyclyl), —N(alkyl)(optionally substituted heterocyclyl), —N(optionally substituted cycloalkyl)(optionally substituted heterocyclyl), optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl.

5. The compound or pharmaceutically acceptable salt thereof of claim 4 , wherein R 8c is an unsubstituted or substituted alkyl chosen from:

6. The compound or pharmaceutically acceptable salt thereof of claim 4 , wherein R 8c is an optionally substituted heterocyclyl chosen from:

or R 8c is an optionally substituted cycloalkyl chosen from:

7. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein W is a group of formula

8. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein W is —O—P-Q-C(R 8a )═C(R 8b )(R 8c ) or —N(R)—P-Q-C(R 8a )═C(R 8b )(R 8c ).

9. The compound or pharmaceutically acceptable salt thereof of claim 7 , wherein m and n are each 1; and A 1 is optionally substituted alkyl, optionally substituted aryl, or optionally substituted heteroaryl.

10. The compound or pharmaceutically acceptable salt thereof of claim 9 , wherein the optional substituents said aryl or heteroaryl of A 1 are one to three groups independently chosen from halo, hydroxy, alkyl, alkoxy, cyano, haloalkyl, —NH 2 , —NH(alkyl), —N(alkyl) 2 , heterocyclyl, aryl, and heteroaryl, and the optional substituents of said alkyl of A 1 are 1-2 groups independently chosen from —N(H)—C(═O)-alkyl, hydroxy, and halo.

11. The compound or pharmaceutically acceptable salt thereof of claim 9 , wherein said optionally substituted aryl of A 1 is 2,5-dichlorophenyl; said optionally substituted heteroaryl of A 1 is 2-pyrazinyl, 4-methyl-3-pyridyl,

or

and said optionally substituted alkyl of A 1 is —CH 3 , —CH(CH(OH)CH 3 )—NH—C(═O)CH(CH 3 ) 2 , or —CH(CH 3 )—NH—C(═O)—CH(CH 3 ) 2 .

12. The compound or pharmaceutically acceptable salt thereof of claim 7 , wherein m and n are each 1; and P is -alkyl-N(R)—, -alkyl-aryl-N(R)—,

13. The compound or pharmaceutically acceptable salt thereof of claim 12 , wherein said -alkyl-N(R)— of P is —(CH 2 ) 4 —N(H)—; said -alkyl-aryl-N(R)— of P is —CH 2 -phenyl-N(CH 3 )—; and said

of P is —CH 2 —O—CH 2 -pyrrolidinyl-.

14. The compound or pharmaceutically acceptable salt thereof of claim 8 , wherein P is

wherein Z is a covalent bond or -alkyl-, wherein said -alkyl- is —(CH 2 ) 1-4 —.

15. The compound or pharmaceutically acceptable salt thereof of claim 14 , wherein said

16. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein R b1 is optionally substituted alkyl, wherein the optional substituents are 1-2 substituents chosen from —O-aryl, —O-heteroaryl, —N(H)-aryl, —N(alkyl)-aryl, —N(H)-heteroaryl, —N(alkyl)-heteroaryl, cycloalkenyl, aryl, heterocyclyl, heterocyclenyl, or heteroaryl; wherein each instance of said aryl, heteroaryl, heterocyclyl, and heterocyclenyl is optionally substituted with 1-3 substituents independently chosen from halo, alkyl, alkoxy, haloalkyl, cyano, —NH 2 , —NH(alkyl), —N(alkyl) 2 , and heterocyclyl.

17. The compound or pharmaceutically acceptable salt thereof of claim 16 , wherein said R b1 is unsubstituted alkyl or a substituted alkyl of the formula —(CH 2 ) 1-2 —R″ wherein R″ is —O-aryl, —O-heteroaryl, —N(H)-aryl, —N(alkyl)-aryl, —N(H)-heteroaryl, —N(alkyl)-heteroaryl, cycloalkenyl, aryl, heterocyclyl, heterocyclenyl, or heteroaryl; wherein each instance of said aryl, heteroaryl, heterocyclyl, and heterocyclenyl is optionally substituted with 1-3 substituents independently chosen from the group consisting of halo, alkyl, alkoxy, haloalkyl, cyano, —NH 2 , —NH(alkyl), —N(alkyl) 2 , and heterocyclyl.

18. The compound or pharmaceutically acceptable salt thereof of claim 16 , wherein said R b1 is chosen from —CH 2 CH(CH 3 ) 2 , —CH 2 C(CH 3 ) 3 , —CH 2 -cyclopentenyl, —CH 2 -phenyl, —CH 2 -phenyl-methyl, —CH 2 -phenyl-ethyl, —CH 2 CH 2 -phenyl, —CH 2 -phenyl-trifluoromethyl, —CH 2 -fluorophenyl, —CH 2 -thiophenyl, —CH 2 —CH 2 -benzofuranyl, —CH 2 CH 2 -benzimidazolyl, —CH 2 CH 2 -dihydroindolyl, —CH 2 -benzofuranyl, —CH 2 -benzimidazolyl, —CH 2 -dihydroindolyl, —CH 2 —O-phenyl, and —CH 2 —N(CH 3 )-phenyl.

19. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein R 8a is hydrogen or cyano; R 8b is hydrogen or alkyl; or R 8a and R 8b are taken together to form a covalent bond; or wherein R 8a , R 8b and R 8c are each hydrogen; or R 8a is halogen, and R 8b and R 8c are each hydrogen.

20. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein R b2 and R b3 are each H; or wherein R b2 and R b3 together with the boron atom to which they are shown attached form an optionally substituted cyclic boronic ester of the formula

21. The compound according claim 1 , wherein the compound is chosen from:

((R)-1-((S)-6-(2-cyano-4-methylpent-2-enamido)-2-((S)-2-isobutyramidopropanamido)hexanamido)-3-methylbutyl)boronic acid;

((R)-1-((S)-6-(2-cyano-4-methylpent-2-enamido)-2-(pyrazine-2-carboxamido)hexanamido)-3-methylbutyl)boronic acid;

((R)-1-((S)-6-(2-cyano-4-methylpent-2-enamido)-2-(2,5-dichlorobenzamido)hexanamido)-3-methylbutyl)boronic acid;

((R)-1-((S)-6-(2-cyano-4-methylpent-2-enamido)-2-((S)-2-isobutyramidopropanamido)hexanamido)-2-phenylethyl)boronic acid;

((R)-1-((S)-6-(2-cyano-4-methylpent-2-enamido)-2-(pyrazine-2-carboxamido)hexanamido)-2-phenylethyl)boronic acid;

((R)-1-((S)-6-(2-cyano-4-methylpent-2-enamido)-2-(6-hydroxypicolinamido)hexanamido)-2-phenylethyl)boronic acid;

((R)-1-((S)-6-(2-cyano-4-methylpent-2-enamido)-2-(6-hydroxypicolinamido)hexanamido)-3-methylbutyl)boronic acid;

((R)-1-((S)-6-(2-cyano-4-methylpent-2-enamido)-2-(6-oxo-1,6-dihydropyridine-2-carboxamido)hexanamido)-2-phenylethyl)boronic acid;

((R)-1-((S)-6-(2-cyano-4-methylpent-2-enamido)-2-(6-oxo-1,6-dihydropyridine-2-carboxamido)hexanamido)-3-methylbutyl)boronic acid;

((R)-1-((S)-6-(2-cyano-4-methylpent-2-enamido)-2-(2,5-dichlorobenzamido)hexanamido)-2-phenylethyl)boronic acid;

((R)-1-((S)-6-(2-cyano-4-methylpent-2-enamido)-2-((2S,3R)-3-hydroxy-2-isobutyramidobutanamido)hexanamido)-3-methylbutyl)boronic acid;

((R)-1-((S)-6-(2-cyano-4-methylpent-2-enamido)-2-((2S,3R)-3-hydroxy-2-isobutyramidobutanamido)hexanamido)-2-phenylethyl)boronic acid;

((R)-1-((S)-2-acetamido-6-(2-cyano-4-methylpent-2-enamido)hexanamido)-2-phenylethyl)boronic acid;

((R)-1-((S)-3-(((R)-1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methoxy)-2-(2,5-dichlorobenzamido)propanamido)-2-phenylethyl)boronic acid;

((R)-1-((S)-2-(2,5-dichlorobenzamido)-3-(3-(N-methylacrylamido)phenyl)propanamido)-2-phenylethyl)boronic acid;

((R)-1-((S)-2-(2,5-dichlorobenzamido)-3-(3-(N-methylvinylsulfonamido)phenyl)propanamido)-2-phenylethyl)boronic acid;

((R)-1-((S)-6-(2-cyano-4-methylpent-2-enamido)-2-(4-methylnicotinamido)hexanamido)-2-phenylethyl)boronic acid;

((R)-1-((S)-2-(2,5-dichlorobenzamido)-3-(3-(N-methylbut-2-ynamido)phenyl)propanamido)-2-phenylethyl)boronic acid;

8-((R)-1-((S)-3-(((R)-1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methoxy)-2-(2,5-dichlorobenzamido)propanamido)-2-phenylethyl)-4-methyl-2,6-dioxohexahydro-[1,3,2]oxazaborolo[2,3-b][1,3,2]oxazaborol-4-ium-8-uide;

((R)-1-((S)-3-(3-(2-cyano-N,4-dimethylpent-2-enamido)phenyl)-2-(2,5-dichlorobenzamido)propanamido)-2-phenylethyl)boronic acid;

((R)-1-((S)-3-(3-(2-cyano-N,4-dimethylpent-2-enamido)phenyl)-2-(pyrazine-2-carboxamido)propanamido)-2-phenylethyl)boronic acid;

((R)-1-((S)-6-(2-cyano-4-methylpent-2-enamido)-2-(methylsulfonamido)hexanamido)-2-phenylethyl)boronic acid;

((R)-1-((S)-6-(2-cyano-4-methylpent-2-enamido)-2-((2,2,2-trifluoroethyl)amino)hexanamido)-2-phenylethyl)boronic acid;

((R)-1-((S)-3-(((R)-1-(2-cyano-4-methylpent-2-enoyl)piperidin-2-yl)methoxy)-2-((2,2,2-trifluoroethyl)amino)propanamido)-2-phenylethyl)boronic acid;

((R)-1-((S)-3-(3-(2-cyano-N,4-dimethylpent-2-enamido)phenyl)-2-((2,2,2-trifluoroethyl)amino)propanamido)-2-phenylethyl)boronic acid;

((R)-1-((S)-3-(3-(2-cyano-N,4-dimethylpent-2-enamido)phenyl)-2-((2,2,2-trifluoroethyl)amino)propanamido)-3-methylbutyl)boronic acid;

((R)-1-((S)-3-(((R)-1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methoxy)-2-((2,2,2-trifluoroethyl)amino)propanamido)-3-methylbutyl)boronic acid;

((R)-1-((S)-3-(((R)-1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methoxy)-2-((2,2,2-trifluoroethyl)amino)propanamido)-2-(3-ethylphenyl)ethyl)boronic acid;

((R)-2-(benzofuran-3-yl)-1-((S)-3-(((R)-1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methoxy)-2-(2,2,2-trifluoroethyl)amino)propanamido)ethyl)boronic acid;

(R)-1-((S)-3-(((R)-1-(2-cyano-3-cyclopropylacryloyl)pyrrolidin-2-yl)methoxy)-2-(2,2,2-trifluoroethylamino)propanamido)-2-phenylethylboronic acid;

(R)-1-((S)-3-(((R)-1-(2-cyano-4-methylpent-2-enoyl)pyrrolidin-2-yl)methoxy)-2-(2,2,2-trifluoroethylamino)propanamido)-2-phenylethylboronic acid;

(R)-1-((S)-3-(((R)-1-(2-cyano-4,4-dimethylpent-2-enoyl)pyrrolidin-2-yl)methoxy)-2-(2,2,2-trifluoroethylamino)propanamido)-2-phenylethylboronic acid;

(R)—(1-(4-(1-(2-cyano-4-methylpent-2-enoyl)piperidin-4-yl)butanamido)-2-phenylethyl)boronic acid;

((R)-1-(2-((R)-1-(2-cyano-4-(3,3-difluoropyrrolidin-1-yl)-4-methylpent-2-enoyl)piperidin-3-yl)acetamido)-2-phenylethyl)boronic acid;

((R)-1-(2-((R)-4-(2-cyano-4-(3,3-difluoropyrrolidin-1-yl)-4-methylpent-2-enoyl)morpholin-2-yl)acetamido)-2-phenylethyl)boronic acid;

((R)-1-(2-((S)-1-(2-cyano-4-(3,3-difluoropyrrolidin-1-yl)-4-methylpent-2-enoyl)piperidin-3-yl)acetamido)-2-phenylethyl)boronic acid;

((R)-1-(2-((S)-4-(2-cyano-4-(3,3-difluoropyrrolidin-1-yl)-4-methylpent-2-enoyl)morpholin-2-yl)acetamido)-2-phenylethyl)boronic acid;

an individual E or Z isomer thereof; and

a pharmaceutically acceptable salt of any of the foregoing compounds.

22. The compound or pharmaceutically acceptable salt thereof of claim 7 , wherein m is 0 and n is 1; and A 1 is optionally substituted alkyl or —S(═O) 2 -alkyl.

23. The compound or pharmaceutically acceptable salt thereof of claim 22 , wherein said optional substituents of alkyl of A 1 are 1-2 substituents chosen from halo, hydroxy, alkoxy, cyano, haloalkyl, —NH 2 , —NH(alkyl), —N(alkyl) 2 , heterocyclyl, aryl, and heteroaryl.

24. The compound or pharmaceutically acceptable salt thereof of claim 7 , wherein m is 0 and n is 1; and P is -alkyl-N(R)—, -alkyl-aryl-N(R)—,

wherein Z is -alkyl-O-alkyl- and ring A with the ring nitrogen atom shown is a monocyclic five-to six-membered heterocyclyl, or

25. The compound or pharmaceutically acceptable salt thereof of claim 7 , wherein m and n are each 0; A 1 is hydrogen; and P is

wherein Z is covalent bond or -alkyl-; and ring A with the ring nitrogen atom shown is piperidinyl or morpholinyl.

26. A pharmaceutical composition comprising at least one compound of claim 1 , or a pharmaceutical acceptable salt thereof, and a pharmaceutically acceptable excipient.

27. A pharmaceutical composition comprising at least one compound of claim 21 , or a pharmaceutical acceptable salt thereof, and a pharmaceutically acceptable excipient.